戒烟及尼古丁戒烟市场机会、成长动力、产业趋势分析及预测（2025-2034）

2024 年全球戒烟和尼古丁脱瘾市场规模达到 255 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 12%。人们越来越意识到吸烟带来的严重健康风险，包括肺癌、心血管疾病和呼吸道疾病，这推动了尼古丁脱瘾产品的需求。政府推动的反吸烟运动、对烟草产品的更严格监管以及消费者对更健康替代品的偏好不断上升，进一步加速了市场扩张。

随着人们对戒烟计画、尼古丁替代疗法 (NRT) 和先进药物配方的日益重视，市场将在未来十年实现大幅成长。此外，药物的进步和下一代尼古丁替代解决方案（如处方药和行为支持疗法）的引入使人们更容易成功戒烟。提供戒烟支援的数位健康平台和行动应用程式的日益普及，进一步促进了人们对这些解决方案的认识和可及性的提高。

市场按产品类型分类，包括尼古丁替代疗法 (NRT)、药物疗法以及电子烟和蒸气烟。 2024 年，电子烟和蒸气烟领域将占据市场主导地位，占总份额的 50%。人们越来越喜欢这些替代品，因为人们认为它们与传统香烟相比危害较小。年轻人，尤其是北美和欧洲的年轻人，正引领着电子烟设备的潮流，他们被电子烟的便利性、口味多样性和技术进步所吸引。越来越多的监管机构批准透过电子烟产品来控制尼古丁输送，以及主要参与者对创新减害技术的投​​资不断增加，进一步推动了该领域的成长。

依给药途径考察市场时，可分为口服、透皮、鼻腔、吸入及舌下给药方式。 2024年，吸入剂领域将占据市场主导地位，占有50%的份额。该领域的主导地位很大程度上归因于尼古丁吸入器、蒸气烟和电子香烟的日益普及。随着吸入疗法的不断进步，製造商推出了新型尼古丁吸入器，旨在提供可控剂量的尼古丁，增强其作为戒烟辅助的有效性。消费者偏好吸入式吸烟方式，是因为它们能够复製传统吸烟的体验，同时最大限度地减少接触有害化学物质。

2024 年美国戒烟和尼古丁戒烟市场价值为 89 亿美元，预计到 2034 年将达到 267 亿美元。美国肺癌和其他吸烟相关疾病的盛行率不断上升，推动了对戒烟产品的需求。越来越多的吸烟者，特别是年轻人，正在积极寻求传统香烟的替代品，导致对 NRT、处方药和行为疗法的需求激增。电子烟和蒸气烟作为戒烟过渡辅助工具的广泛采用进一步支持了市场的成长。预计不断扩大的研发力度以及政府支持的反吸烟措施将在未来几年为市场参与者创造重大机会。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 人们对吸烟相关健康风险的认识不断提高
    • 政府法规和反吸烟运动
    • 戒烟产品的进步
    • 吸烟相关疾病和医疗成本上升
  • 产业陷阱与挑战
    • 戒烟产品成本高
    • 心理和生理成瘾挑战
• 成长潜力分析
• 技术格局
• 监管格局
• 差距分析
• 专利分析
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：依产品类型，2021 年至 2034 年

• 主要趋势
• 尼古丁替代疗法
  • 尼古丁口香糖
  • 尼古丁贴片
  • 尼古丁含片
  • 尼古丁鼻喷剂
  • 尼古丁吸入器
• 药物治疗
  • 伐尼克兰（Chantix）
  • 安非他酮（Zyban）
• 电子烟和蒸气烟

第六章：市场估计与预测：依管理路线，2021 年至 2034 年

• 主要趋势
• 口服
• 透皮
• 鼻腔
• 吸入
• 舌下

第七章：市场估计与预测：按配销通路，2021 年至 2034 年

• 主要趋势
• 医院药房
• 零售药局
• 电子商务

第八章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• Alkalon
• British American Tobacco
• Cipla
• Dr. Reddy's Laboratories
• GlaxoSmithKline
• Imperial Brands
• Johnson & Johnson
• Lupin
• NJOY
• Novartis
• Perrigo Company
• Pfizer
• Philip Morris International
• Rusan Pharma
• Zydus Group

The Global Smoking Cessation And Nicotine De-Addiction Market reached USD 25.5 billion in 2024 and is projected to grow at a CAGR of 12% between 2025 and 2034. The increasing awareness of the severe health risks associated with smoking, including lung cancer, cardiovascular diseases, and respiratory disorders, is fueling the demand for nicotine de-addiction products. Government initiatives promoting anti-smoking campaigns, stricter regulations on tobacco products, and rising consumer preference for healthier alternatives are further accelerating market expansion.

With a growing emphasis on smoking cessation programs, nicotine replacement therapies (NRT), and advanced drug formulations, the market is poised for substantial growth over the coming decade. Additionally, pharmaceutical advancements and the introduction of next-generation nicotine replacement solutions, such as prescription medications and behavioral support therapies, are making it easier for individuals to quit smoking successfully. The rising adoption of digital health platforms and mobile applications offering smoking cessation support is further contributing to the growing awareness and accessibility of these solutions.

The market is categorized by product type, including nicotine replacement therapy (NRT), drug therapy, and E-cigarettes and vapes. In 2024, the E-cigarettes and vapes segment dominated the market, accounting for 50% of the total share. The rising preference for these alternatives stems from their perceived reduced harm compared to conventional cigarettes. Young adults, particularly in North America and Europe, are leading the shift toward vaping devices, attracted by their convenience, variety of flavors, and technological advancements. Increasing regulatory approvals for controlled nicotine delivery through vaping products and growing investments by key players in innovative, harm-reduction technologies are further driving segment growth.

When examining the market by the route of administration, it is segmented into oral, transdermal, nasal, inhalation, and sublingual methods. In 2024, the inhalation segment led the market, holding a 50% share. The segment's dominance is largely attributed to the rising adoption of nicotine inhalers, vapes, and E-cigarettes. With continuous advancements in inhalation-based therapies, manufacturers are introducing novel nicotine inhalers designed to deliver controlled doses of nicotine, enhancing their effectiveness as a smoking cessation aid. Consumer preference for inhalation methods is driven by their ability to replicate the experience of traditional smoking while minimizing exposure to harmful chemicals.

The U.S. Smoking Cessation and Nicotine De-Addiction Market was valued at USD 8.9 billion in 2024 and is projected to reach USD 26.7 billion by 2034. The increasing prevalence of lung cancer and other smoking-related diseases in the U.S. is driving the demand for smoking cessation products. A growing number of smokers, particularly young adults, are actively seeking alternatives to traditional cigarettes, leading to a surge in demand for NRT, prescription medications, and behavioral therapies. The widespread adoption of E-cigarettes and vapes as a transitional aid for quitting smoking is further supporting market growth. Expanding research and development efforts, alongside government-backed anti-smoking initiatives, are expected to create significant opportunities for market players in the coming years.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing awareness of health risks associated with smoking
    • 3.2.1.2 Government regulations and anti-smoking campaigns
    • 3.2.1.3 Advancements in smoking cessation products
    • 3.2.1.4 Rise in smoking-related diseases and healthcare costs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of smoking cessation products
    • 3.2.2.2 Psychological and physical addiction challenges
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Gap analysis
• 3.7 Patent analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Nicotine replacement therapy
  • 5.2.1 Nicotine gum
  • 5.2.2 Nicotine patches
  • 5.2.3 Nicotine lozenges
  • 5.2.4 Nicotine nasal sprays
  • 5.2.5 Nicotine inhalers
• 5.3 Drug therapy
  • 5.3.1 Varenicline (Chantix)
  • 5.3.2 Bupropion (Zyban)
• 5.4 E-cigarettes and vapes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Transdermal
• 6.4 Nasal
• 6.5 Inhalation
• 6.6 Sublingual

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Alkalon
• 9.2 British American Tobacco
• 9.3 Cipla
• 9.4 Dr. Reddy’s Laboratories
• 9.5 GlaxoSmithKline
• 9.6 Imperial Brands
• 9.7 Johnson & Johnson
• 9.8 Lupin
• 9.9 NJOY
• 9.10 Novartis
• 9.11 Perrigo Company
• 9.12 Pfizer
• 9.13 Philip Morris International
• 9.14 Rusan Pharma
• 9.15 Zydus Group